New combo therapy for lung scarring and high blood pressure under study
NCT ID NCT07333183
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new inhaled drug, mosliciguat, added to an existing treatment (treprostinil) for people with high blood pressure in the lungs caused by lung scarring. The goal is to see if the combination is safe and tolerable. About 20 adults with this condition will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Florida Lung, Asthma & Sleep Specialists/Clinical Research Specialists, LLC
RECRUITINGKissimmee, Florida, 34746, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••